N/A
Manufactured by ROERIG
48,526 FDA adverse event reports analyzed
Last updated: 2026-04-14
DOXAZOSIN is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by ROERIG. The most commonly reported adverse reactions for DOXAZOSIN include DYSPNOEA, DIZZINESS, FATIGUE, DRUG INEFFECTIVE, DIARRHOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DOXAZOSIN.
Out of 27,046 classified reports for DOXAZOSIN:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 48,526 FDA FAERS reports that mention DOXAZOSIN. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DYSPNOEA, DIZZINESS, FATIGUE, DRUG INEFFECTIVE, DIARRHOEA, ACUTE KIDNEY INJURY. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list ROERIG in connection with DOXAZOSIN. Always verify the specific product and NDC with your pharmacist.